109 related articles for article (PubMed ID: 3192057)
1. [Changes in the level of extracellular DNA and free polyamines in the blood of patients with chronic myeloleukemia].
Pan'kov VN; Voronchikhina LD; Dem'ianova VT; Beznosikova TP; Kolupaeva NV
Gematol Transfuziol; 1988 Aug; 33(8):45-8. PubMed ID: 3192057
[No Abstract] [Full Text] [Related]
2. [An atypical form of chronic myeloleukemia].
Shapiro AE; Donskaia SB; Drozdova VD; Kireeva SS
Vrach Delo; 1989 Aug; (8):30-1. PubMed ID: 2588520
[No Abstract] [Full Text] [Related]
3. Treatment of chronic myelogenous leukemia with interferons: hematologic, cellular, and genetic investigations.
Opalka B; Kloke O; Wandl U; Becher R; Niederle N
Haematol Blood Transfus; 1989; 32():134-8. PubMed ID: 2516494
[No Abstract] [Full Text] [Related]
4. [The character of quantitative changes in some parameters of polyamine metabolism of the blood in patients with chronic leukemia].
Voronchikhina LD; Dem'ianova VT; Berdinskikh NK; Kolupaeva NV; Beznosikova TP
Vopr Med Khim; 1989; 35(1):74-7. PubMed ID: 2500778
[TBL] [Abstract][Full Text] [Related]
5. [The prognostic factors in chronic myeloleukemia].
Khoroshko ND
Ter Arkh; 1993; 65(7):23-8. PubMed ID: 8211773
[TBL] [Abstract][Full Text] [Related]
6. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease in chronic myeloid leukemia.
Löwenberg B
N Engl J Med; 2003 Oct; 349(15):1399-401. PubMed ID: 14534331
[No Abstract] [Full Text] [Related]
8. Secondary chronic myelogenous leukemia: a diverse pathogenesis?
Aguiar RC; Beitler B; Dorlhiac-Llacer PE; Chamone DA
Acta Haematol; 1994; 92(2):101-3. PubMed ID: 7817701
[TBL] [Abstract][Full Text] [Related]
9. [The megakaryoblastic variant of the blast crisis in chronic myeloleukemia].
Volkova MA; Frenkel' MA; Lepkov SV; Tupitsyn NN
Ter Arkh; 1990; 62(7):127-9. PubMed ID: 2251650
[No Abstract] [Full Text] [Related]
10. Long-template DNA polymerase chain reaction for the detection of the bcr/abl translocation in patients with chronic myelogenous leukemia.
Waller CF; Dennebaum G; Feldmann C; Lange W
Clin Cancer Res; 1999 Dec; 5(12):4146-51. PubMed ID: 10632353
[TBL] [Abstract][Full Text] [Related]
11. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up.
; Simonsson B
Ann Oncol; 2007 Apr; 18 Suppl 2():ii51-2. PubMed ID: 17491046
[No Abstract] [Full Text] [Related]
12. [Criteria of differential diagnosis of chronic myeloproliferative diseases].
Shardakov VI; Kopaneva TG; Dem'ianova VT
Gematol Transfuziol; 1991 Jun; 36(6):3-4. PubMed ID: 1769495
[TBL] [Abstract][Full Text] [Related]
13. Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy.
Foa P; Iurlo A; Orazi A; Saglio G; Ribera S; Bertoni F; Caldiera S; Fornier M; Maiolo AT
Acta Haematol; 1997; 97(3):187-8. PubMed ID: 9066716
[No Abstract] [Full Text] [Related]
14. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
15. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
16. Plicamycin-hydroxyurea association in chronic granulocytic leukemia and multidrug resistance.
Papineschi F; Carulli G; Petrini M
Haematologica; 1991; 76(4):349. PubMed ID: 1686602
[No Abstract] [Full Text] [Related]
17. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
[TBL] [Abstract][Full Text] [Related]
18. The combined use of busulfan and hydroxyurea in the treatment of chronic myeloid leukemia.
Jim RT
Hawaii Med J; 1990 Apr; 49(4):133-4. PubMed ID: 2341244
[No Abstract] [Full Text] [Related]
19. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
Maiti A; Cortes J; Ferrajoli A; Estrov Z; Borthakur G; Garcia-Manero G; Jabbour E; Ravandi F; O'Brien S; Kantarjian H
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28278723
[No Abstract] [Full Text] [Related]
20. [The use of interferon-alfa (reaferon) in patients with chronic myeloleukemia].
Machiulaĭtene ER; Lasunskaia EB; Nefedova IuB; Perekalina TA; Salogub GN; Poliakova LE
Ter Arkh; 1996; 68(10):44-7. PubMed ID: 9026942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
